PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
复制标题
Xp11.2 易位肾细胞癌中的 PD-L1 表达：肿瘤侵袭性指标
DOI：
10.1038/s41598-017-02005-7
复制
发表时间：
2017-05-18
影响因子：
4.6
通讯作者：
Ye D
中科院分区：
文献类型：
--
作者：
Chang K;Qu Y;Dai B;Zhao JY;Gan H;Shi G;Zhu Y;Shen Y;Zhu Y;Zhang H;Ye D
程序性死亡配体-1（PD-L1）是一个很有前途的抗肿瘤靶点，已被证明对许多恶性肿瘤具有临床价值。然而，Xp11.2易位肾细胞癌（Xp11.2 RCC）的PD-L1含量及其与临床结局的相关性尚不清楚。本研究旨在研究Xp11.2 RCC中PD-L1的表达并评估其预后价值。福尔马林固定石蜡包埋标本从36例成人患者，组织学证实（荧光原位杂交）进行免疫组化分析。在36例Xp11.2 RCC患者中，9例（25.0%）肿瘤PD-L1表达阳性，27例（75.0%）肿瘤PD-L1表达阴性。PD-L1阳性表达与肿瘤晚期（P = 0.001）、区域淋巴结转移（P 0.001）和远处转移（P 0.001）相关。多变量分析发现，PD-L1阳性表达是无进展生存期（风险比：3.7，P = 0.018）和总生存期（风险比：4.5，P = 0.034）的独立不良预后因素。整个队列的中位PFS和OS分别为13.0个月（95%置信区间[CI]，9.4-16.6个月）和36.0个月（95% CI，23.9-48.1个月）。我们的研究结果表明，PD-L1阳性表达是Xp11.2 RCC临床结局较差的指标。需要进一步的研究来探索靶向PD-L1在Xp11.2 RCC中的潜在疗效。
Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investigate PD-L1 expression in Xp11.2 RCC and to assess its prognostic value. Formalin-fixed paraffin-embedded specimens from 36 adult patients that were histologically confirmed (by fluorescence in situ hybridization) were subjected to immunohistochemical analysis. Of the 36 Xp11.2 RCC patients, 9 (25.0%) had tumors with positive PD-L1 expression and 27 (75.0%) had tumors with negative PD-L1 expression. Positive PD-L1 expression correlated with advanced tumor stage (P = 0.001), regional lymph node metastasis (P 0.001), and distant metastasis (P 0.001). A multivariate analysis identified positive PD-L1 expression was an independent adverse prognostic factor for both progression free survival (hazard ratio: 3.7, P = 0.018) and overall survival (hazard ratio: 4.5, P = 0.034). The median PFS and OS for the whole cohort were 13.0 months (95% confidence interval [CI], 9.4–16.6 months) and 36.0 months (95% CI, 23.9–48.1 months), respectively. Our findings suggest that positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 RCC. Further studies are needed to explore the potential efficacy of targeting PD-L1 in Xp11.2 RCC.